Analysis File of Drug-Induced Lung Injury : Expert Opinion for Analysis of Big Data / by Akihiko Gemma.

Format:

Book

Author/Creator:

Gemma, Akihiko.

Series:

Medicine Series

Language:

English

Subjects (All):

Respiratory organs--Diseases.

Respiratory organs.

Medical genetics.

Diseases--Causes and theories of causation.

Diseases.

Oncology.

Pharmacology.

Genetics--Research.

Genetics.

Pneumology.

Clinical Genetics.

Pathogenesis.

Genetics Research.

Local Subjects:

Pneumology.

Clinical Genetics.

Pathogenesis.

Oncology.

Pharmacology.

Genetics Research.

Physical Description:

1 online resource (122 pages)

Edition:

1st ed. 2024.

Place of Publication:

Singapore : Springer Nature Singapore : Imprint: Springer, 2024.

Summary:

This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.

Contents:

Part I Understanding Drug-Induced Lung Injuries

1 Understanding Drug-Induced Lung Injuries

Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug

2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib)

3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab)

4 mTOR inhibitors (temsirolimus, everolimus)

5 Proteasome inhibitor (bortezomib)

6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab)

7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab)

8 Other molecular targeted drugs (crizotinib, alectinib, etc.)

9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan)

10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.).

Notes:

Description based on publisher supplied metadata and other sources.

Other Format:

Print version: Gemma, Akihiko Analysis File of Drug-Induced Lung Injury

ISBN:

9789819734467

OCLC:

1450873394